Home Newsfeeds Chardan Capital Downgrades Evelo Biosciences to Neutral, Announces $2.5 Price Target

Chardan Capital Downgrades Evelo Biosciences to Neutral, Announces $2.5 Price Target

Chardan Capital analyst Keay Nakae downgrades Evelo Biosciences (NASDAQ:EVLO) from Buy to Neutral and announces $2.5 price target.

byBenzinga Newsdesk

November 16, 2022

1 minute read

Chardan Capital analyst Keay Nakae downgrades Evelo Biosciences (NASDAQ:EVLO) from Buy to Neutral and announces $2.5 price target.

General Motors, Samsung SDI Plan To Build EV Battery Plant Worth $3B In Indiana: Report

By Nabaparna Bhattacharya

June 13, 10:58 AM

General Motors Company (NYSE: GM) and South Korea-based Samsung SDI (OTC: SSDIY) reportedly plan to construct an electric vehicle battery cell plant worth more than $3 billion in Indiana.

iPhone 14 Pro Models Preorders Reflect Loyal and Sticky Customers Amid Economic Slowdown, Apple Analyst Says

By Anusuya Lahiri

September 12, 10:52 AM

Analyst Ming-Chi Kuo

AAPL

News

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial In The United States For The Treatment Of Individuals With Multiple System Atrophy

By Charles Gross

January 8, 8:45 PM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.

ATHE

Apple Supplier Foxconn Says Rumors Of People With COVID-19 Living In Dorms Untrue Amid Violent Protests

By Navdeep Yadav

November 23, 6:14 AM

Foxconn Technology (OTC:HNHPF) said some new hires “appealed” to the company regarding the work allowance after videos of…